2010
Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo-controlled trial.
Saricicek A, Maloney K, Muralidharan A, Ruf B, Blumberg HP, Sanacora G, Lorberg B, Pittman B, Bhagwagar Z. Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo-controlled trial. The Journal Of Clinical Psychiatry 2010, 72: 744-50. PMID: 21034692, DOI: 10.4088/jcp.09m05659gre.Peer-Reviewed Original ResearchConceptsDepression Rating ScaleRating ScaleMean changeWeek 6Clinical Global Impression-Bipolar Version ScaleBipolar disorderHamilton Depression Rating Scale scoresMontgomery-Åsberg Depression Rating ScalePlacebo-controlled clinical trialDepression Rating Scale scoresHamilton Depression Rating ScaleYoung Mania Rating ScaleAdjunctive levetiracetam therapyLevetiracetam adjunctive therapySecondary efficacy assessmentsBipolar disorder type IPlacebo-controlled trialHamilton Anxiety Rating ScalePrimary efficacy measureSecondary outcome measuresMajor depressive episodeRating Scale scoresMania Rating ScaleShort-term treatmentSignificant differencesAntidepressant Response and the Serotonin Transporter Gene-Linked Polymorphic Region
Taylor MJ, Sen S, Bhagwagar Z. Antidepressant Response and the Serotonin Transporter Gene-Linked Polymorphic Region. Biological Psychiatry 2010, 68: 536-543. PMID: 20615496, PMCID: PMC2929304, DOI: 10.1016/j.biopsych.2010.04.034.Peer-Reviewed Original Research
2004
Persistent reduction in brain serotonin1A receptor binding in recovered depressed men measured by positron emission tomography with [11C]WAY-100635
Bhagwagar Z, Rabiner E, Sargent P, Grasby P, Cowen P. Persistent reduction in brain serotonin1A receptor binding in recovered depressed men measured by positron emission tomography with [11C]WAY-100635. Molecular Psychiatry 2004, 9: 386-392. PMID: 15042104, DOI: 10.1038/sj.mp.4001401.Peer-Reviewed Original ResearchConceptsMajor depressionDepressed menDepressed subjectsAcute major depressionPositron emission tomography studyPotentials of brainEmission tomography studiesRecurrent major depressionPositron emission tomographyStatistical parametric mappingReceptor BPReference tissue modelAntidepressant medicationPersistent dysfunctionRaphe nucleusUnmedicated subjectsHealthy controlsBP valuesCortical areasTrait abnormalityMale subjectsEmission tomographyPersistent reductionTomography studyReceptor bindingInositol for depressive disorders
Taylor M, Wilder H, Bhagwagar Z, Geddes J. Inositol for depressive disorders. Cochrane Database Of Systematic Reviews 2004, 2004: cd004049. PMID: 15106232, PMCID: PMC6984679, DOI: 10.1002/14651858.cd004049.pub2.Peer-Reviewed Original ResearchMeSH KeywordsAntidepressive AgentsDepressive DisorderHumansInositolRandomized Controlled Trials as TopicConceptsTreatment of depressionCochrane Controlled Trials RegisterControlled Trials RegisterTrials RegisterAdjunctive therapyDepressive disorderNeurosis Controlled Trials RegisterCochrane Collaboration DepressionAcceptability of treatmentDouble-blind designShort-term trialsAntidepressant medicationDATA COLLECTIONTherapeutic benefitAlternative treatmentReference listsAffective disordersEffective interventionsTerm trialsAdverse effectsTrialsPoor acceptabilityDepressionTreatmentDisorders
2003
Risperidone augmentation decreases rapid eye movement sleep and decreases wake in treatment-resistant depressed patients.
Sharpley A, Bhagwagar Z, Hafizi S, Whale W, Gijsman H, Cowen P. Risperidone augmentation decreases rapid eye movement sleep and decreases wake in treatment-resistant depressed patients. The Journal Of Clinical Psychiatry 2003, 64: 192-6. PMID: 12633128, DOI: 10.4088/jcp.v64n0212.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultAntidepressive AgentsAntipsychotic AgentsCross-Over StudiesDepressive DisorderDose-Response Relationship, DrugDouble-Blind MethodFemaleHumansMaleMiddle AgedPersonality InventoryPlacebosPolysomnographyPsychiatric Status Rating ScalesRisperidoneSleep, REMTreatment OutcomeWakefulnessConceptsRapid eye movement (REM) sleepEye movement sleepDepressed patientsHealthy volunteersRisperidone treatmentMovement sleepREM sleepMedication-resistant depressed patientsTreatment-resistant depressed patientsConventional antidepressant medicationAntidepressant-like effectsAntipsychotic agent risperidoneDepression Rating ScaleMajor depressive disorderDSM-IV criteriaPatients meritRisperidone additionRisperidone augmentationAntidepressant medicationRisperidone administrationSingle doseTherapeutic dosesAugmentation agentsDepressive disorderHealthy subjects